Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Fagan Associates Inc.

Fagan Associates Inc. lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 42.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,923 shares of the biopharmaceutical company’s stock after purchasing an additional 3,832 shares during the period. Regeneron Pharmaceuticals comprises 1.5% of Fagan Associates Inc.’s portfolio, making the stock its 18th largest position. Fagan Associates Inc.’s holdings in Regeneron Pharmaceuticals were worth $9,205,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in REGN. Rakuten Securities Inc. raised its holdings in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at $37,000. Private Wealth Management Group LLC raised its holdings in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 39 shares in the last quarter. Finally, Truvestments Capital LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at $39,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $680.00 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $74.34 billion, a price-to-earnings ratio of 17.76, a PEG ratio of 2.26 and a beta of 0.08. The firm has a 50-day moving average of $702.67 and a two-hundred day moving average of $889.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the company earned $11.86 EPS. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Robert W. Baird dropped their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. Bernstein Bank dropped their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.